498 Bruton’s tyrosine kinase (BTK) inhibitors impede platelet aggregation but not adhesion to collagen.

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy2026
2. 2Differential modulation of Bruton's tyrosine kinase inhibitor selectivity on platelet <scp>GPVI</scp> and integrin <scp>αIIbβ3</scp> bidirectional signalling via <scp>BTK</scp>/<scp>PLCγ2</scp>/<scp>PKCθ</scp> affects haemostasis and thrombosis2025
3. 3Inhibition of platelet kinase signaling and scaffolding activities with small molecule proteolysis-targeting chimeras (PROTACs)2025
4. 4Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting2026 · 2 citations
5. 5Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia2024 · 1 citations